Location History:
- Daejeon, KR (2023)
- Seongnam-si, KR (2024)
Company Filing History:
4 out of 15 
1 out of 25 
1 out of 93 
Years Active: 2023-2024
Title: Innovations in Cancer Treatment: The Patents of Jaehyun Eom
Introduction: Jaehyun Eom is a prominent inventor based in Seongnam-si, South Korea, who has made significant contributions to the field of cancer treatment through his innovative ideas and inventions. With a total of three patents, Eom focuses on the development of bispecific antibodies aimed at addressing complex medical challenges.
Latest Patents: Jaehyun Eom's latest patents include groundbreaking inventions that have the potential to transform cancer therapy. One of his notable patents is the **Anti-EGFR/anti-4-1BB bispecific antibody**, which provides an innovative approach to treating and preventing cancer through a unique pharmaceutical composition. Additionally, he developed a **bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor**. This invention specifically targets alpha-synuclein and IGF1R, facilitating the treatment or diagnosis of synucleinopathies associated with alpha-synuclein aggregates. Notably, the IGF1R component enhances the antibody’s ability to penetrate the blood-brain barrier, allowing effective action within the brain and extending its half-life for prolonged efficacy.
Career Highlights: Eom's professional journey includes impactful roles at various leading companies. He has worked with Abl Bio Inc. and Yuhan Corporation, where he contributed to crucial research and development initiatives focused on innovative therapeutics.
Collaborations: Throughout his career, Jaehyun Eom has collaborated with fellow researchers and professionals, including Eunsil Sung and Yeunju Kim. These collaborations have likely enhanced the quality and scope of his research, leading to notable advancements in his field.
Conclusion: Jaehyun Eom stands out as an influential inventor in the realm of cancer treatment innovations. His patents reflect a commitment to developing solutions that not only target aggressive diseases but also improve the overall quality of life for patients. With a focus on bispecific antibodies, Eom continues to pave the way for future advancements in medical therapeutics.